Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 39

Results For "ITU"

2207 News Found

MGM Healthcare builds world’s largest intestinal transplant program in 3 years
Hospitals | March 27, 2026

MGM Healthcare builds world’s largest intestinal transplant program in 3 years

Since launching, the hospital has performed over 40 intestinal transplants, including 21 in 2025 alone


Alkem Laboratories launches affordable semaglutide injection in India
News | March 26, 2026

Alkem Laboratories launches affordable semaglutide injection in India

Alkem’s semaglutide comes in a pre-filled disposable injection pen containing four doses for a month, priced at Rs. 1,800


Zealand Pharma launches major US research hub in Cambridge, Massachusetts
R&D | March 26, 2026

Zealand Pharma launches major US research hub in Cambridge, Massachusetts

The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities


ImmunityBio scores first Asian approval for ANKTIVA in Macau
News | March 25, 2026

ImmunityBio scores first Asian approval for ANKTIVA in Macau

The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency


Siemens Healthineers expands radiotherapy beyond cancer, targets osteoarthritis pain
News | March 25, 2026

Siemens Healthineers expands radiotherapy beyond cancer, targets osteoarthritis pain

The radiotherapy systems include TrueBeam, TrueBeam STx, VitalBeam, and Edge


Glenmark slashes cost barrier with India launch of GLIPIQ diabetes therapy
News | March 23, 2026

Glenmark slashes cost barrier with India launch of GLIPIQ diabetes therapy

The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety


Zydus launches affordable Semaglutide in India after patent expiry
News | March 23, 2026

Zydus launches affordable Semaglutide in India after patent expiry

Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders


Pfizer’s TALZENNA combo shows breakthrough results in aggressive prostate cancer
Clinical Trials | March 21, 2026

Pfizer’s TALZENNA combo shows breakthrough results in aggressive prostate cancer

The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival